Rosetta Biosoftware
NYSE : MRK

Rosetta Biosoftware

March 29, 2006 11:00 ET

Almac Diagnostics Licenses the Rosetta Resolver Expression Data Analysis System

CRAIGAVON, Northern Ireland and SEATTLE--(CCNMatthews - Mar 29, 2006) -

Almac Diagnostics and Rosetta Biosoftware announced today that Almac Diagnostics (formerly ArraDx Ltd) licensed the Rosetta Resolver® system for use in the development of novel microarray-based approaches for diagnosing cancer and predicting therapeutic outcomes. The Resolver system will also be used in the provision of comprehensive gene expression analysis services offered by Almac Diagnostics to academic, biotech and pharmaceutical customers.

"We are pleased to continue to expand our business by supporting cancer diagnostic research," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "The Resolver system provides a flexible platform to enable researchers to use microarray data in a large biological context, such as the development of disease-specific microarrays for diagnosing cancer."

"At Almac Diagnostics, we are dedicated to promoting discovery," said Professor Paul Harkin, CEO of Almac Diagnostics. "Almac Diagnostics is pioneering a novel transcriptomics-based approach to develop tools, which will radically improve diagnosis and treatment of cancer. The Resolver system provides the comprehensive solution necessary for us to advance this type of research and realize more targeted and personalized approaches for cancer diagnosis and prognosis. Furthermore, our use of the Resolver system will allow all our service customers to benefit from state-of-the-art technology in gene expression data management, analysis and visualization."

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.

About Almac Diagnostics and Almac Sciences

Almac Diagnostics -- a division of the Almac Sciences Group -- develops, markets and supplies, leading-edge genomic expression services and products.

Almac Diagnostics has two divisions:

The Genomic Services business provides all inclusive gene expression and bioinformatic services to academia, biotech and pharmaceutical companies. These services include analysis on our unique disease specific arrays, which provide the ability to detect the maximum information in a given cancer type. Almac Diagnostics is the first Authorised Affymetrix Service Provider to successfully gain accreditation to ISO17025 for our comprehensive Gene Expression Microarray and Bioinformatics services.

The Research & Development Division develops, using proprietary arrays, new tests that will change the way cancers are managed in the future. These proprietary arrays provide unique information for individual cancer types and represent a stable, long-term platform for the development of clinical diagnostics.

www.almac-diagnostics.com

Almac Sciences is a global, knowledge-based leader in the research, development and delivery of pharmaceutical services. Its services, provided by affiliated companies -- CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and Almac Diagnostics -- extend through all phases of drug discovery and clinical trials to the commercialisation of pharmaceutical product. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland, with additional operations in London and Edinburgh.

www.almac-sciences.com

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

Contact Information

  • Rosetta Biosoftware
    Lisa Owen, 206-926-1236
    or
    Almac Sciences
    Paul Harkin, +44 (0)2838 397575